Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (2958)	11/23/1997 4:39:00 PM
From: Joe E.	Read Replies (1) of 6136

John W.: your last two posts mention LMoss and his estimates. Ask him yourself, but I think he has included expanded double protease inhibitor use in his estimates, as he took me to task on this point several weeks ago. More re Friday's fall: In addition to the option expiration madness, there was an article on ABC's online news site about AIDS research: abcnews.com which was a brief recitation about the immense and growing research into this disease area. No new news, just more of the same, really. I can remember (was it last year?) when there was serious doubt about all of the research investments into AIDS treatment ever generating a profit. The whole market potential was thought to be less than $1 billion. Now it is clear that Viracept alone will likely pass that number.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next